- Home
- ANAB vs WIW Comparison
ANAB vs WIW Comparison
Compare ANAB & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- WIW
- Stock Information
- Founded
- ANAB 2005
- WIW 2004
- Country
- ANAB United States
- WIW United States
- Employees
- ANAB N/A
- WIW N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- ANAB Health Care
- WIW Finance
- Exchange
- ANAB Nasdaq
- WIW Nasdaq
- Market Cap
- ANAB 621.1M
- WIW 536.0M
- IPO Year
- ANAB 2017
- WIW N/A
- Fundamental
- Price
- ANAB $20.14
- WIW $8.80
- Analyst Decision
- ANAB Buy
- WIW
- Analyst Count
- ANAB 10
- WIW 0
- Target Price
- ANAB $48.00
- WIW N/A
- AVG Volume (30 Days)
- ANAB 500.2K
- WIW 229.9K
- Earning Date
- ANAB 08-06-2025
- WIW 01-01-0001
- Dividend Yield
- ANAB N/A
- WIW 11.14%
- EPS Growth
- ANAB N/A
- WIW N/A
- EPS
- ANAB N/A
- WIW N/A
- Revenue
- ANAB $123,164,000.00
- WIW N/A
- Revenue This Year
- ANAB N/A
- WIW N/A
- Revenue Next Year
- ANAB $24.39
- WIW N/A
- P/E Ratio
- ANAB N/A
- WIW N/A
- Revenue Growth
- ANAB 304.17
- WIW N/A
- 52 Week Low
- ANAB $12.21
- WIW $8.01
- 52 Week High
- ANAB $40.70
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- ANAB 31.39
- WIW 52.60
- Support Level
- ANAB $19.55
- WIW $8.78
- Resistance Level
- ANAB $22.03
- WIW $8.87
- Average True Range (ATR)
- ANAB 1.50
- WIW 0.05
- MACD
- ANAB -0.53
- WIW 0.00
- Stochastic Oscillator
- ANAB 12.05
- WIW 53.13
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.